HIP14L Inhibitors
HIP14L inhibitors, also known as Huntingtin-interacting protein 14-like inhibitors, constitute a chemical class of compounds designed to modulate the activity of HIP14L, a member of the palmitoyl acyltransferase (PAT) enzyme family. These inhibitors are primarily developed for research purposes and hold potential for understanding the biological functions of HIP14L. HIP14L, a protein with multiple transmembrane domains, plays a crucial role in the post-translational modification of proteins through palmitoylation, a lipidation process that attaches palmitic acid to cysteine residues of target proteins. Palmitoylation serves as a critical regulatory mechanism in cell signaling, protein localization, and membrane association, making HIP14L an intriguing target for scientific investigation.
HIP14L inhibitors function by selectively binding to HIP14L and interfering with its enzymatic activity. This inhibition prevents the transfer of palmitic acid to target proteins, thereby altering their subcellular localization and function. By modulating palmitoylation, researchers can gain insights into the roles of specific palmitoylated proteins in cellular processes, signaling pathways, and diseases. HIP14L inhibitors are valuable tools for probing the intricate mechanisms of protein palmitoylation and its impact on cellular physiology. Researchers employ these inhibitors to explore the functional consequences of palmitoylation on protein-protein interactions, membrane trafficking, and signal transduction, shedding light on the intricate regulatory networks governing cellular function. Additionally, HIP14L inhibitors have applications in studying neurological disorders, as HIP14L is linked to Huntington's disease, a neurodegenerative condition, though their precise role in disease mechanisms remains an active area of research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib inhibits the activities of CDK4 and CDK6. It effectively blocks cell cycle progression at the G1 phase, leading to the inhibition of cell proliferation. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib targets and inhibits multiple receptor tyrosine kinases, including VEGFR and PDGFR. By inhibiting the kinase activity of these receptors, sunitinib disrupts signal transduction pathways essential for tumor growth and angiogenesis. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase by directly blocking its ATP-binding site. This inhibition prevents the activation of the EGFR signaling pathway, which is crucial for cellular processes like cell growth and division. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus inhibits the mTOR kinase by directly binding to its complex, particularly mTORC1. This binding leads to a disruption in protein synthesis and cell proliferation by affecting downstream signaling pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib blocks the activity of EGFR by competitively inhibiting its ATP binding site. This action halts downstream signaling pathways that are vital for the proliferation and survival of cancer cells. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Vemurafenib specifically targets and inhibits the BRAF V600E kinase. It does so by binding to the kinase's ATP-binding site, disrupting the MAPK/ERK signaling pathway, which plays a vital role in the proliferation of melanoma cells. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib serves as a dual inhibitor of EGFR and HER2 tyrosine kinases. It achieves this by binding to the ATP-binding sites of these receptors, preventing their phosphorylation and subsequent activation of downstream signaling pathways involved in cell proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib acts by inhibiting multiple kinases, such as VEGFR, RAF, and PDGFR. This broad-spectrum inhibition disrupts critical signaling pathways that are essential for tumor cell proliferation and angiogenesis, effectively reducing tumor growth and spread. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD 0332991 inhibits CDK4 and CDK6 by interfering with their kinase activity. This interference results in the halting of the cell cycle in the G1 phase, thereby preventing the proliferation of cells. | ||||||